| Date Filed | Type | Description |
| 10/02/2023 |
8-K
| Quarterly results |
| 08/17/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/17/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/17/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/09/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/20/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/09/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 05/05/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/01/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/21/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/06/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/05/2023 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 04/05/2023 |
SC 13D/A
| RTW INVESTMENTS, LP reports a 23% stake in Rocket Pharmaceuticals, Inc. |
| 04/04/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/31/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 02/28/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/27/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 02/24/2023 |
CERT
| Form CERT - Certification by an exchange approving securities for listing: |
| 02/23/2023 |
8-A12B
| Form 8-A12B - Registration of securities [Section 12(b)]: |
| 02/09/2023 |
SC 13G/A
| VANGUARD GROUP INC reports a 5.3% stake in Rocket Pharmaceuticals Inc. |
| 02/07/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 02/06/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/31/2023 |
SC 13G/A
| BlackRock Inc. reports a 7.1% stake in ROCKET PHARMACEUTICALS, INC. |
| 01/31/2023 |
SC 13G
| STATE STREET CORP reports a 5% stake in INITIAL FILING ROCKET PHARMACEUTICALS INC |
| 01/09/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Investor Presentation of Rocket Pharmaceuticals, Inc",
"CRANBURY, N.J. – Jan. 9, 2023 – Rocket Pharmaceuticals, Inc. , a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces the addition of RP-A601 to Rocket’s cardiac gene therapy portfolio as well as anticipated highlights for the year ahead across the Company’s world-class pipeline of lentiviral and AAV gene therapy programs targeting rare hematologic and cardiovascular diseases. These announcements and anticipated highlights will be presented at the 41st Annual J.P. Morgan Healthcare Conference today at 2:15 p.m. PT by Gaurav Shah, M.D., Chief Executive Officer, Rocket Pharma." |
|
| 12/22/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 12/20/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 12/01/2022 |
8-K
| Quarterly results |
| 11/04/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/03/2022 |
8-K
| Quarterly results |
| 10/27/2022 |
S-4/A
| Form S-4/A - Registration of securities, business combinations: [Amend] |
|